136 related articles for article (PubMed ID: 30759288)
1. Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit.
de Nonneville A; Jauffret C; Gonçalves A; Classe JM; Cohen M; Reyal F; Mazouni C; Chauvet MP; Chopin N; Colombo PE; Jouve E; Darai E; Rouzier R; Coutant C; Gimbergues P; Azuar AS; de Lara CT; Lambaudie E; Houvenaeghel G
Breast Cancer Res Treat; 2019 Jun; 175(2):379-387. PubMed ID: 30759288
[TBL] [Abstract][Full Text] [Related]
2. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database.
Hu G; Hu G; Zhang C; Lin X; Shan M; Yu Y; Lu Y; Niu R; Ye H; Wang C; Xu C
BMC Cancer; 2020 Feb; 20(1):136. PubMed ID: 32085753
[TBL] [Abstract][Full Text] [Related]
4. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer.
Criscitiello C; Disalvatore D; De Laurentiis M; Gelao L; Fumagalli L; Locatelli M; Bagnardi V; Rotmensz N; Esposito A; Minchella I; De Placido S; Santangelo M; Viale G; Goldhirsch A; Curigliano G
Breast; 2014 Feb; 23(1):69-75. PubMed ID: 24314620
[TBL] [Abstract][Full Text] [Related]
5. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
[TBL] [Abstract][Full Text] [Related]
6. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
[TBL] [Abstract][Full Text] [Related]
7. Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.
Metzger-Filho O; Procter M; de Azambuja E; Leyland-Jones B; Gelber RD; Dowsett M; Loi S; Saini KS; Cameron D; Untch M; Smith I; Gianni L; Baselga J; Jackisch C; Bell R; Sotiriou C; Viale G; Piccart-Gebhart M
J Clin Oncol; 2013 Jun; 31(16):1954-60. PubMed ID: 23589556
[TBL] [Abstract][Full Text] [Related]
8. Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma.
Adachi Y; Ishiguro J; Kotani H; Hisada T; Ichikawa M; Gondo N; Yoshimura A; Kondo N; Hattori M; Sawaki M; Fujita T; Kikumori T; Yatabe Y; Kodera Y; Iwata H
BMC Cancer; 2016 Mar; 16():248. PubMed ID: 27015895
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy in patients with invasive lobular carcinoma and use of the 21-gene recurrence score: A National Cancer Database analysis.
Weiser R; Polychronopoulou E; Hatch SS; Haque W; Ghani HA; He J; Kuo YF; Gradishar WJ; Klimberg VS
Cancer; 2022 May; 128(9):1738-1747. PubMed ID: 35137951
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes using accelerated partial breast irradiation in patients with invasive lobular carcinoma.
Shah C; Wilkinson JB; Shaitelman S; Grills I; Wallace M; Mitchell C; Vicini F
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e547-51. PubMed ID: 21640491
[TBL] [Abstract][Full Text] [Related]
12. HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights.
Da Ros L; Moretti A; Querzoli P; Pedriali M; Lupini L; Bassi C; Carcoforo P; Negrini M; Frassoldati A
Clin Breast Cancer; 2018 Oct; 18(5):e1133-e1139. PubMed ID: 29759595
[TBL] [Abstract][Full Text] [Related]
13. Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis.
van de Water W; Fontein DB; van Nes JG; Bartlett JM; Hille ET; Putter H; Robson T; Liefers GJ; Roumen RM; Seynaeve C; Dirix LY; Paridaens R; Kranenbarg EM; Nortier JW; van de Velde CJ
Eur J Cancer; 2013 Jan; 49(2):297-304. PubMed ID: 22954666
[TBL] [Abstract][Full Text] [Related]
14. The clinical value of adjuvant radiotherapy in patients with early stage breast cancer with 1 to 3 positive lymph nodes after mastectomy.
Wu SG; He ZY; Li FY; Wang JJ; Guo J; Lin Q; Guan XX
Chin J Cancer; 2010 Jul; 29(7):668-76. PubMed ID: 20591219
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
de Nonneville A; Gonçalves A; Zemmour C; Cohen M; Classe JM; Reyal F; Colombo PE; Jouve E; Giard S; Barranger E; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
Eur J Cancer; 2017 Oct; 84():34-43. PubMed ID: 28780480
[TBL] [Abstract][Full Text] [Related]
16. Influence of histology on the effectiveness of adjuvant chemotherapy in patients with hormone receptor positive invasive breast cancer.
Truin W; Voogd AC; Vreugdenhil G; van der Sangen MJ; van Beek MW; Roumen RM
Breast; 2011 Dec; 20(6):505-9. PubMed ID: 21665471
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast.
Zengel B; Yararbas U; Duran A; Uslu A; Elıyatkın N; Demırkıran MA; Cengiz F; Şimşek C; Postacı H; Vardar E; Durusoy R
Breast Cancer; 2015 Jul; 22(4):374-81. PubMed ID: 23925582
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
19. Effect of histological breast cancer subtypes invasive lobular versus non-special type on survival in early intermediate-to-high-risk breast carcinoma: results from the SUCCESS trials.
Dayan D; Lukac S; Rack B; Ebner F; Fink V; Leinert E; Veselinovic K; Schütze S; El Taie Z; Janni W; Friedl TWP
Breast Cancer Res; 2023 Dec; 25(1):153. PubMed ID: 38098086
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of chemotherapy in patients with HR+/HER2-Invasive lobular breast cancer.
Yaghi M; Bilani N; Dominguez B; Zerdan MB; Li H; Saravia D; Stone E; Nahleh Z
Cancer Treat Res Commun; 2023; 34():100666. PubMed ID: 36525755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
